Answers are grounded in this paper and cite their sources.
This review highlights the importance of lipoprotein lipase in triglyceride metabolism and outlines emerging therapies targeting this pathway for hypertriglyceridemia.
Moderately elevated plasma triglyceride levels contribute to increased risk for cardiovascular disease, whereas severe hypertriglyceridemia (fasting plasma triglyceride >10 mmol/l) is associated with an increased risk of pancreatitis. The enzyme lipoprotein lipase (LpL) plays an essential role in triglyceride metabolism. Mild decreases in LpL activity are thought to contribute to the hypertriglyceridemic atherogenic phenotype in Type 2 diabetes and the metabolic syndrome, whereas complete deficiency of LpL results in severe hypertriglyceridemia as a testimony to its importance in triglyceride homeostasis. The purpose of this article is to assess the role of LpL and its cofactors in triglyceride metabolism. Moreover, the currently available therapeutic strategies and the novel treatment modalities that are under development targeting LpL or its cofactors, such as antisense Apo-CIII, LpL gene therapy and novel compounds that influence LpL activity (NO-1886) for patients with primary hypertriglyceridemia will be discussed.
No takes yet. Share an insight, caveat, or question.
David Alpers (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: